scholarly journals Late-onset multiple acyl-CoA dehydrogenase deficiency mimicking myositis in an elderly patient: a case report

BMC Neurology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Yiming Zheng ◽  
Yawen Zhao ◽  
Wei Zhang ◽  
Zhaoxia Wang ◽  
Yun Yuan

Abstract Background Late-onset multiple acyl-CoA dehydrogenase deficiency (MADD) is a rare and treatable inherited lipid storage myopathy. Here, we report an elderly patient with MADD mimicking myositis. Case presentation An 80-year-old woman had progressive weakness in her limbs, exercise intolerance, and no muscle pain for 3 months. The patient’s serum creatine kinase level was slightly elevated. The initial diagnosis was myositis. However, muscle biopsy showed many cytoplasmic vacuoles stained with oil red O, indicating the presence of lipid storage myopathy. The plasma acylcarnitine profile showed increased medium-chain and long-chain acylcarnitine species, consistent with the diagnosis of MADD. Riboflavin treatment dramatically improved muscle weakness. Conclusions MADD should be considered when evaluating elderly patients with subacute muscle weakness.

BMC Neurology ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Wei Chen ◽  
Youqiao Zhang ◽  
Yifeng Ni ◽  
Shaoyu Cai ◽  
Xin Zheng ◽  
...  

Abstract Background Multiple acyl-CoA dehydrogenase deficiency (MADD) is a riboflavin-responsive lipid-storage myopathy caused by mutations in the EFTA, EFTB or ETFDH genes. We report a Chinese family of Southern Min origin with two affected siblings with late-onset riboflavin-responsive MADD due to a homozygous c.250G > A EFTDH mutation and review the genetic epidemiology of the c.250G > A mutation. Case presentation Both siblings presented with exercise-induced myalgia, progressive proximal muscle weakness and high levels of serum muscle enzymes and were initially diagnosed as polymyositis after a muscle biopsy. A repeat biopsy in one sibling subsequently showed features of lipid storage myopathy and genetic analysis identified a homozygous mutation (c.250G > A) in the ETFDH gene in both siblings and carriage of the same mutation by both parents. Glucocorticoid therapy led to improvement in muscle enzyme levels, but little change in muscle symptoms, and only after treatment with riboflavin was there marked improvement in exercise tolerance and muscle strength. The frequency and geographic distribution of the c.250G > A mutation were determined from a literature search for all previously reported cases of MADD with documented mutations. Our study found the c.250G > A mutation is the most common EFTDH mutation in riboflavin-responsive MADD (RR-MADD) and is most prevalent in China and South-East Asia where its epidemiology correlates with the distribution and migration patterns of the southern Min population in Southern China and neighbouring countries. Conclusions Mutations in ETFDH should be screened for in individuals with lipid-storage myopathy to identify patients who are responsive to riboflavin. The c.250G > A mutation should be suspected particularly in individuals of southern Min Chinese background.


Author(s):  
Yiming Lin ◽  
Weifeng Zhang ◽  
Zhixu Chen ◽  
Chunmei Lin ◽  
Weihua Lin ◽  
...  

Abstract Objectives Multiple acyl-CoA dehydrogenase deficiency (MADD) is an autosomal recessive disorder of fatty acid, amino acid and choline metabolism. Late-onset MADD is caused by ETFDH mutations and is the most common lipid storage myopathy in China. However, few patients with MADD have been identified through newborn screening (NBS). This study assessed the acylcarnitine profiles and molecular features of patients with MADD identified through NBS. Methods From January 2014 to June 2020, 479,786 newborns screened via tandem mass spectrometry were recruited for this study. Newborns with elevated levels of multiple acylcarnitines were recalled, those who tested positive in the reassessment were referred for genetic analysis. Results Of 479,786 newborns screened, six were diagnosed with MADD. The MADD incidence in the Chinese population was estimated to be 1:79,964. Initial NBS revealed five patients with typical elevations in the levels of multiple acylcarnitines; however, in one patient, acylcarnitine levels were in the normal reference range during recall. Notably, one patient only exhibited a mildly increased isovalerylcarnitine (C5) level at NBS. The patient with an atypical acylcarnitine profile was diagnosed with MADD by targeted gene sequencing. Six distinct ETFDH missense variants were identified, with the most common variant being c.250G>A (p.A84T), with an allelic frequency of 58.35 (7/12). Conclusions These findings revealed that it is easy for patients with MADD to go unidentified, as they may have atypical acylcarnitine profiles at NBS and the recall stage, indicating the value of genetic analysis for confirming suspected inherited metabolic disorders in the NBS program. Therefore, false-negative (FN) results may be reduced by combining tandem mass spectrometry (MS/MS) with genetic testing in NBS for MADD.


2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Keechilat Pavithran ◽  
Divya Pachat ◽  
Dehannathparambil Kottarathil Vijaykumar

Abstract Background Multiple acyl-CoA dehydrogenase deficiency (MAAD) is a rare metabolic disorder resulting from an abnormality in fatty acid oxidation. There are three types of presentations: neonatal onset with or without congenital anomalies and the late-onset type. There is much clinical heterogeneity in the presentation of late-onset variants; hence, the diagnosis is often delayed or missed. Case presentation Here, we report the successful management of a 41-year-old female with late-onset MAAD due to mutation in the ETFDH gene who presented with carcinoma of the breast. Chemotherapy was challenging because there were no previous reports regarding the treatment of such cases. Conclusion The diagnosis was made based on metabolic workup and gene mutation analysis. Unplanned surgery and chemotherapy can be fatal in these patients due to metabolic complications. With proper precautions and monitoring, the patient tolerated surgery and chemotherapy without any complications.


1984 ◽  
Vol 311 (19) ◽  
pp. 1232-1236 ◽  
Author(s):  
Douglass M. Turnbull ◽  
Kim Bartlett ◽  
David L. Stevens ◽  
K. George M. M. Alberti ◽  
G. John Gibson ◽  
...  

1992 ◽  
Vol 32 (3) ◽  
pp. 170-176 ◽  
Author(s):  
T. Mongini ◽  
C. Doriguzzi ◽  
L. Palmucci ◽  
A. De Francesco ◽  
L. Bet ◽  
...  

Neurology ◽  
1998 ◽  
Vol 51 (2) ◽  
pp. 598-600 ◽  
Author(s):  
Anthony A. Amato ◽  
Robert T. Shebert

Sporadic inclusion body myositis (s-IBM) is characterized by late onset of slowly progressive weakness that involves the quadriceps and volar forearm muscles early in the course of the disease. There are hereditary forms of inclusion body myopathy (h-IBM) that histologically resemble s-IBM. The lack of inflammation on biopsy and the different ages at onset and patterns of muscle weakness distinguish s-IBM from h-IBM. We report twin brothers with the typical clinical and histologic features of s-IBM. The occurrence of s-IBM in these twins suggests the possibility of a genetic susceptibility to developing s-IBM.


2017 ◽  
Vol 381 ◽  
pp. 702
Author(s):  
S. Okune ◽  
A. Ishii ◽  
N. Tozaka ◽  
A. Shioya ◽  
A. Tamaoka

2018 ◽  
Vol 89 (6) ◽  
pp. A12.2-A12
Author(s):  
Wai Foong Hooi ◽  
Christopher Kyndt ◽  
Mark Faragher ◽  
Bruce Day

IntroductionMultiple-acyl-CoA dehydrogenase deficiency or MADD is a rare autosomal recessive disorder caused by deficiency of electron transfer flavoprotein. Late onset form of MADD typically present with slowly progressive proximal weakness, myalgia, lethargy, vomiting, hypoglycaemia and metabolic acidosis. This condition is highly variable in age and symptoms at onset. The mean delay between onset of symptoms and diagnosis was 3.9 years. Confirmation of the diagnosis requires relatively complicated tests including muscle biopsy, Acylcarnitine profiling, urinary organic acid analysis and molecular gene testing. MADD responds dramatically to riboflavin supplementation and dietary treatment i.e. high carbohydrate, low fat and low protein diet. We report of a case of Multiple-Acyl-CoA Dehydrogenase Deficiency (MADD) and a review of the literature.CaseA 22 year old female presented with 3 year history of slowly progressive muscle weakness, fatigue and dyspnea on minimal exertion. Clinical examination revealed profound neck extension weakness (‘dropped head syndrome’), proximal muscle weakness (winged scapula and positive Gower’s sign), mild dysphagia and dysarthria. There was no obvious facial weakness, ptosis or ophthalmoplegia. Muscle biopsy showed prominent lipid and generalised hypotrophy of type I fibres. The diagnosis of MADD was suspected on the basis of clinical presentation. The patient was commenced on riboflavin, carnitine supplementation and low protein, low fat diet. Her symptoms improved significantly over 2 months (improvement in muscle strength and respiratory function, FVC improved from 42% to 89%). Acylcarnitine and amino acid screen results came back later showing elevated levels of C6, C8, C10 and C12 in keeping with the diagnosis of MADD.ConclusionMultiple-acyl-CoA dehydrogenase deficiency is a rare genetic metabolic myopathy. It is under-recognised and diagnosis of the adult onset form is often challenging. The majority of patients respond well to riboflavin and dietary modifications with excellent clinical outcome.References. Sharp LJ, Haller RG. Metabolic and mitochondrial myopathies. Neurol Clin2014Aug;32:777–99.. Grunert SC. Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme: A dehydrogenase deficiency. Orphanet J Rare Dis2014Jul 22;9:117.. Angelini C. Spectrum of metabolic myopathies. Biochem Biophys Acta2015Apr;1852(4):615–21.. Yee WC. Two eminently treatable genetic metabolic myopathies. Neurol India2008Jul–Sep;56(3):333–8.


2010 ◽  
Vol 78 (6) ◽  
pp. 565-569 ◽  
Author(s):  
M-Y Lan ◽  
M-H Fu ◽  
Y-F Liu ◽  
C-C Huang ◽  
Y-Y Chang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document